Registration in Brazil

9 May 2005 07:00

LiDCO Group Plc09 May 2005 LiDCO GROUP PLC ("LiDCO" or "the Company") Product Registration in Brazil - Largest Medical Market in Latin America LiDCO Group plc (AIM: LID), the UK-based cardiovascular monitoring company, ispleased to announce today that registration of the LiDCOplus Monitor, associateddisposables and lithium chloride injection have been approved for sale inBrazil. Brazil is the largest medical market in Latin America with around 7,200hospitals and an estimated hospital services market of $5 billion. The full launch of LiDCO's products in Brazil will take place at the 3rdInternational Symposium on Intensive Care & Emergency Medicine for LatinAmerica, June 21- 25th in Sao Paulo. Terry O'Brien, Chief Executive of LiDCO, stated: "Brazil is the biggest LatinAmerican market for our products. This is the fifth additional country that wehave added to our sales territories in 2005. We expect the successful conclusionto these registration activities will contribute to further sales growth duringthe year." Mario Padovani, Managing Director of LiDCO's Brazilian distributor, Bragenix,said: "I am delighted that the LiDCO products have been approved for sale. Thisis especially good timing because the recently published trial results showingmajor reductions in surgical complications obtained at St George's Hospital willbe presented at our June critical care symposium in Sao Paulo. We are excitedabout developing a very strong market for LiDCO's products in Brazil." For further information please contact: LiDCO Group PlcTerry O'Brien (CEO) terry@lidco.com 020 7749 1500Hugh McGarel-Groves (FD) hugh.mcgarelgroves@lidco.com Buchanan CommunicationsTim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Notes for Editors About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base. The Company's manufacturing facility is in Hoxton, London and its currentproducts are: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitor accurately determine cardiac output in a minimally-invasive manner. Distribution Network: Following today's announcement the Company has now achieved registration of itsproducts in 13 markets in Europe, the USA, Brazil and Japan. It sells direct tothe NHS in the UK, and through a worldwide network of specialty critical caredistributors. Background to the recently published clinical trial: Better than standard care -(EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO'sminimally invasive monitoring technology were presented during the 25thInternational Symposium on Intensive Care and Emergency Medicine in Brussels(21st to 25th March). The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000 per patient. Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62 patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significant reduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissue oxygen levels following surgery. This information is provided by RNS The company news service from the London Stock Exchange